Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia

Leukemia Research

Volumn 24, Issue 7, 2000, Pages

  Bushman, Jennifer E ^a   Palmieri, Diane ^b   Whinna, Herbert C ^b,d   Church, Frank C ^b,c,d  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Division of Hematology/Oncology   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antithrombin III; Childhood acute lymphoblastic leukemia; L asparaginase; Liver protein synthesis; Thrombosis

Indexed keywords

ANTITHROMBIN III; ASPARAGINASE; ASPARAGINE; BLOOD CLOTTING FACTOR 10A; HEPARIN COFACTOR II; LIVER PROTEIN; SERINE PROTEINASE INHIBITOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BLOOD; CANCER CELL CULTURE; CELL STRAIN HEPG2; CELL VIABILITY; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CULTURE MEDIUM; DEPLETION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; ANTITHROMBIN III; ASPARAGINASE; CELL SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PLASMA; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SERPINS; TUMOR CELLS, CULTURED;

EID: 0343729893     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00017-5     Document Type: Article

References (37)

1. Rivera G.K., Crist W.M. Acute lymphoblastic /leukemia. Handlin R.I., Stossel T.P., Lux S.E. Blood: Principles and Practice of Hematology. 1995;743 Lippincott, Philadelphia.
2. Cortes J.E., Kantarjian H.M. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer. 76:1995;2393.
3. Freedman AS, Nadler LM. In: Braunwald E, Fauci AS, Isselbacher KJ, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Malignancies of Lymphoid Cells (ch. 113). New York Harrison's Online http://www.harrisonsonline.com/hill-bin/Chapters.cgi.
4. Pui C.-H., Evans W.E. Acute lymphoblastic leukemia. New Engl. J. Med. 339:1998;605.
5. Bauer K.A., Teitel J.M., Rosenberg R.D. L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb. Res. 29:1983;437.
6. Anderson N., Lokich J.J., Tullis J.L. L-asparaginase effect on antithrombin-III levels. Med. Pediatr. Oncol. 7:1979;335.
7. Pitney W.R., Phadke K.P., Dean S. Antithrombin III deficiency during asparaginase therapy. Lancet. I:1980;493.
8. Vellenga E., Mulder N.H., Nieweg H.O. Antithrombin III deficiency during asparaginase therapy. Lancet. I:1980;649.
9. Priest J.R., Ramsay N.K.C., Bennett A.J., Krivit W., Edson J.R. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J. Pediatr. 100:1982;990.
10. Liebman H.A., Wada J.K., Patch M.J., McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer. 50:1982;451.
11. Homans A.C., Rybak M.E., Baglini R.L., Tiarks C., Steiner M.E., Forman E.N. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J. Clin. Oncol. 5:1987;811.
12. Shapiro A.D., Clarke S.L., Christian J.M., Odom L.F., Hathaway W.E. Thrombosis in children receiving L-asparaginase. Determining patients at risk. Am. J. Pediatr. Hematol. Oncol. 15:1993;400.
13. Andrew M., Brooker L., Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul. Fibrinolysis. 5:1994;S24.
14. Mitchell L., Hoogendoorn H., Giles A.R., Vegh P., Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood. 83:1994;386.
15. Nowak-Gottl U., Boos J., Wolff J.E.A., Lill H., Veltmann H., Werber G., Ahlke E., Jurgens H. Asparaginase decreases clotting factors in vitro: a possible pitfall? Int. J. Clin. Lab. Res. 25:1995;146.
16. Mitchell L.G., Sutor A.H., Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin. Thromb. Hemost. 21:1995;390.
17. Roberts HR, Lozier JN. New perspectives on the coagulation cascade. Hosp. Pract. 1992:97.
18. Church FC, Cunningham DD, Ginsburg D, Hoffman M, Stone SR, Tollefsen DM, editors. Chemistry and Biology of Serpins. New York: Plenum Press, 1997.
19. Nowak-Gottl U., Kuhn N., Wolff J.E.A., Boos J., Kehrel B., Rath B., Jurgens H. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur. J. Haematol. 56:1996;35.
20. Nowak-Gottl U., Rath B., Binder M., Hassel J.-U., Wolff J., Husemann S., Ritter J. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica. 80:1995;451.
21. Halton J.M., Mitchell L.G., Vegh P., Eves M., Andrew M.E. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am. J. Hematol. 47:1994;157.
22. Pogliani E.M., Parma M., Baragetti I., Mostarda G., Rivolta F., Maffe P., Corneo G. L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy. Acta Haematol. 93:1995;5.
23. Griffith M.J., Noyes C.M., Church F.C. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J. Biol. Chem. 260:1985;2218.
24. Church F.C., Whinna H.C. Rapid sulfopropyl-disk chromatographic purification of bovine and human thrombin. Anal. Biochem. 157:1986;77.
25. Frohwein Y.Z., Friedman M., Reizer J., Grossowicz N. Sensitive and rapid assay for L-asparaginase. Nat. New Biol. 230:1971;158.
26. Capizzi R.L., Handschumacher R.E. Asparaginase. Holland J.R., Frei E. Cancer Medicine. 1973;850 Lea & Fibiger.
27. Whinna H.C., Blinder M.A., Szewczyk M., Tollefsen D.M., Church F.C. Role of lysine 173 in heparin binding to heparin cofactor II. J. Biol. Chem. 266:1991;8129.
28. Pratt C.W., Tobin R.B., Church F.C. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. J. Biol. Chem. 265:1990;6092.
29. Bauman S.J., Church F.C. Enhancement of heparin cofactor II anticoagulant activity. J. Biol. Chem. 274:1999;34556.
30. Odegard O.R., Lie M., Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis. 5:1976;265.
31. Palmieri D., Watson J.M., Rinehart C.A. Age-related expression of PEDF/EPC-1 in human endometrial stromal fibroblasts: implications for interactive senescence. Exp. Cell Res. 247:1999;142.
32. Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 83:1983;55.
33. Watson J.M., Parrish E.A., Rinehart C.A. Selective potentiation of gynecologic cancer cell growth in vitro by electromagnetic fields. Gynecol. Oncol. 71:1998;64.
34. Cairo M.S. Adverse reactions of L-asparaginase. Am. J. Pediatr. Hematol./Oncol. 4:1982;335.
35. Conard J., Cazenave B., Maury J., Horellou M.H., Samama M. L-asparaginase, antithrombin III, and thrombosis. Lancet. I:1980;1091.
36. Capizzi R.L., Bertino J.R., Skeel R.T., Creasey W.A., Zanes R., Olayon C., Peterson R.G., Handschumacher R.E. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann. Intern. Med. 74:1971;893.
37. Humphries J.E. Thromophilia and complex acquired deficiencies of antithrombin, protein C, and protein S. Semin. Hematol. 32:1995;8.